Biocon Ltd. (BION)

Currency in INR
365.10
+3.10(+0.86%)
Closed·

BION Earnings

Latest Release
Nov 04, 2026
EPS / Forecast
0.30 / 0.97
Revenue / Forecast
43.89B / 45.93B
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/12--/1.24--/48.53B----Free Sign Up
2026/090.300/0.96843.89B/45.93B-69.01%-4.44%Free Sign Up
2026/060.870/0.91043.36B/44.77B-4.4%-3.15%Free Sign Up
2026/031.20/1.3745.17B/45.41B-12.41%-0.53%Free Sign Up
2025/120.947/1.1441.73B/45.20B-16.91%-7.68%Free Sign Up
2025/090.758/0.75042.96B/41.81B+1.01%+2.75%Free Sign Up
2025/060.260/0.71439.42B/39.88B-63.59%-1.15%Free Sign Up
2025/032.87/1.7144.17B/41.82B+67.84%+5.62%Free Sign Up
2024/120.210/1.0338.56B/39.09B-79.61%-1.36%Free Sign Up
2024/09-0.130/0.55035.90B/36.36B-123.64%-1.27%Free Sign Up

All numbers in INR

Biocon Ltd. Earnings Call Summary for Q2/2027

  • Biocon posted 6% H1 FY2027 revenue growth to INR 8,725 crore with 20% EBITDA margin; Q2 revenue rose just 2% year-over-year to INR 865 crore.
  • One-time logistics delay deferred ~5% of Q2 biosimilar revenue (INR 135-138 crore) into October; management expects stronger H2 performance.
  • YESINTEK holds 34% U.S. market share; YESAFILI has 50%+ access; $400M Brazil pertuzumab contract begins Q4 FY2027, U.S. launch set for Q3 2028.
  • Shares rose 0.19% to $343.65 in muted reaction; stock trades 23% below 52-week high despite 'excellent' financial health score from InvestingPro.
  • CEO Tambe emphasized focus on margins, free cash flow, and debt reduction; interest costs fell 12% year-over-year as deleveraging continues.
Last Updated: 2026-11-04, 06:42 a/m
Read Full Transcript

FAQ

What Is Biocon's Earnings Per Share (TTM)?

The Biocon EPS (TTM) is 2.94.

When Is The Next Biocon Earnings Date?

Biocon will release its next earnings report on Feb 04, 2027.

What Is Biocon’s Revenue Forecasts For Upcoming Quarters?

Biocon’s revenue forecast is 48.53B.

How Did Biocon React to the Company's Latest Earnings Report?

Biocon reported a -69.01% EPS surprise and a -4.44% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 5.54%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.